2016
DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.001
|View full text |Cite
|
Sign up to set email alerts
|

Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
17
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 35 publications
0
17
0
Order By: Relevance
“…Miscarriage, proliferative changes, increased levels of chromogranin A, increased levels of fibroblast growth factor 2, chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido, rhinitis, dementia, metabolic syndrome and hepatic steatosis, low sperm motility, increased risk of fibrosis progression, cirrhosis, hepatic decompensation and development of hepatocellular carcinoma. [44][45][46][47][48]60,[65][66][67] DI (n = 6)…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Miscarriage, proliferative changes, increased levels of chromogranin A, increased levels of fibroblast growth factor 2, chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido, rhinitis, dementia, metabolic syndrome and hepatic steatosis, low sperm motility, increased risk of fibrosis progression, cirrhosis, hepatic decompensation and development of hepatocellular carcinoma. [44][45][46][47][48]60,[65][66][67] DI (n = 6)…”
Section: Discussionmentioning
confidence: 99%
“…The frequency of adverse reactions was classified according to the leaflet of the reference drug product, except for the 28 studies for which there was no information on the leaflet. 80 3* 2* 3* Galante et al, 2012 96 4* 1* 3* Lin et al, 2012 81 4* 2* 3* David-Neto et al, 2012 49 4* 1* 3* Soriano et al, 2014 16 4* 2* 3* Chen et al, 2014 28 4* 2* 3* Wang et al, 2017 97 4* 2* 3* Gomm et al, 2016 44 4* 2* 3* Yi et al, 2017 47 4* 2* 3* Varallo et al, 2018 41 4* 2* 3* Imperatore et al, 2018 45 4* 2* 3* Lazzerini et al, 2018 42 4* 1* 3* Li et al, 2018 48 4 Table 3. Continuation Several drug interactions relating to omeprazole, especially with antiplatelet agents, are known.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…CYP2C19*2, *3 are loss-of-function alleles, and CYP2C19*17 is gain-of-function allele [30] . those without loss-of-function allele (*1/*1) are classi ed as extensive metabolizers [31] . Patients carrying *1 and *17 alleles (*1/*17 or *17/*17) are classi ed as ultra-metabolizers [32] .…”
Section: Cyp2c19 Genotype and 11-dhtxb2 Testsmentioning
confidence: 99%
“…Individuals with complete information for each of the 3 SNPs will be included in the current analyses. [30,31] . Those with at least 1 loss-of-function allele (*2 or *3) are classified as loss-of-function allele carriers and those with at least 1 gain-of-function allele (*17) are classified as gain-of-function allele carriers [32] .…”
Section: Cyp2c19 Genotyping and 11-dhtxb2 Testingmentioning
confidence: 99%